<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e8f6d534-115c-440e-bdbb-b443a29bb468"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">YUTREPIA™</content> safely and effectively.  See full prescribing information for <content styleCode="bold">YUTREPIA™</content>.<br/>
      <br/>
      <content styleCode="bold">YUTREPIA™ (treprostinil) inhalation powder, for oral inhalation</content>
      <br/>Initial U.S. Approval: 2002</title>
   <effectiveTime value="20250523"/>
   <setId root="e8f6d534-115c-440e-bdbb-b443a29bb468"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="157103164" root="1.3.6.1.4.1.519.1"/>
            <name>Liquidia Technologies, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="01bfbb54-4279-49ee-bc82-0f69fd7998dd"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250523"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="72964-011"/>
                        <name>Yutrepia</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>treprostinil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="ug" value="26.5"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7JZ75N2NT6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREPROSTINIL SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RUM6K67ESG" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TREPROSTINIL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEUCINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C92708" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="7"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="72964-011-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250523"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213005" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250523"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">LIQUIDIA;26;5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="72964-012"/>
                        <name>Yutrepia</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>treprostinil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="ug" value="53"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7JZ75N2NT6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREPROSTINIL SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RUM6K67ESG" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TREPROSTINIL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEUCINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C92708" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="7"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="72964-012-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250523"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213005" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250523"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GREEN" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">LIQUIDIA;53</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="72964-013"/>
                        <name>Yutrepia</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>treprostinil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="ug" value="79.5"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7JZ75N2NT6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREPROSTINIL SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RUM6K67ESG" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TREPROSTINIL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEUCINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C92708" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="7"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="72964-013-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250523"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213005" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250523"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">LIQUIDIA;79;5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code codeSystem="2.16.840.1.113883.6.69" code="72964-014"/>
                        <name>Yutrepia</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>treprostinil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="ug" value="106"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7JZ75N2NT6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREPROSTINIL SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RUM6K67ESG" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TREPROSTINIL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TREHALOSE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEUCINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C92708" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="4"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="7"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="72964-014-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250523"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA213005" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250523"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PURPLE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">LIQUIDIA;106</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RESPIRATORY (INHALATION)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_768ca9b9-5e90-445f-8868-40167cd31211">
               <id root="3a15efac-f0ba-4e65-a2ff-b62202c2cea2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). (<linkHtml href="#ID_8d822845-50a5-4e25-9c3f-eb718fa8a596">1.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). (<linkHtml href="#ID_3072bfb4-4502-44ae-9fc8-7da27969ed9b">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8d822845-50a5-4e25-9c3f-eb718fa8a596">
                     <id root="f802754b-4807-4947-960d-d6c25ae6ef9f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Pulmonary Arterial Hypertension </title>
                     <text>
                        <paragraph>YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).</paragraph>
                        <paragraph>The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. </paragraph>
                        <paragraph>While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_127d9518-e71f-47d6-b341-8889ffa0f6a2">14</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3072bfb4-4502-44ae-9fc8-7da27969ed9b">
                     <id root="b75a796a-e8cd-46ec-9c3c-0149cbf19426"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Pulmonary Hypertension Associated with ILD </title>
                     <text>
                        <paragraph>YUTREPIA is indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_55bc5520-e509-48d0-9d25-58a93adc2014">14.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e510ec96-93c6-4947-aeff-9f3bf29284c9">
               <id root="34ba5e47-e0a5-40a9-8c30-713bf05b4de1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For oral inhalation only. Do not swallow YUTREPIA capsules. Use only with the provided inhaler (<linkHtml href="#ID_e510ec96-93c6-4947-aeff-9f3bf29284c9">2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>YUTREPIA should be administered 3 to 5 times per day. The contents of each capsule can be inhaled in 2 breaths. (<linkHtml href="#ID_d2cda3e3-3e80-4616-81f8-1fb436ca6509">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>See <content styleCode="italics">Dosage and Administration</content> for full instructions on dosing of patients who are treprostinil-naïve or transitioning from treprostinil inhalation solution to YUTREPIA (<linkHtml href="#ID_d2cda3e3-3e80-4616-81f8-1fb436ca6509">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_d2cda3e3-3e80-4616-81f8-1fb436ca6509">
                     <id root="19b921be-c288-4944-94c0-6370cf5f5377"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Usual Dosage In Adults </title>
                     <text>
                        <paragraph>YUTREPIA capsules are for oral inhalation only and should be used only with the supplied inhaler. </paragraph>
                        <paragraph>
                           <content styleCode="italics">YUTREPIA Dosing in treprostinil-naïve patients</content>:</paragraph>
                        <paragraph>In patients naïve to treprostinil, therapy should begin with 26.5 mcg 3 to 5 times per day, in 2 breaths based on patient response.  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Dosing in patients transitioning from treprostinil inhalation solution (Tyvaso)</content>:</paragraph>
                        <paragraph>Patients transitioning from treprostinil inhalation solution (Tyvaso), can begin YUTREPIA therapy 3 to 5 times per day, in 2 breaths, using the doses specified below (<linkHtml href="#_Ref198876245" title="Table 1">Table 1</linkHtml>):</paragraph>
                        <table ID="_Ref198876245" width="50%" cellpadding="3.6pt">
                           <caption>Table 1: YUTREPIA Dosing in Patients Transitioning from Treprostinil Inhalation Solution</caption>
                           <col width="28%"/>
                           <col width="28%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="2">*Each breath of Tyvaso delivers approximately 6 mcg of treprostinil.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Current Tyvaso Dose*</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">YUTREPIA Dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Breaths</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">mcg</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Toprule ">
                                    <paragraph>≤5</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule ">
                                    <paragraph>26.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>≥6 and ≤8</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>53</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>≥9 and ≤11</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>79.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>≥12 and ≤14</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>106</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>≥15 and ≤17</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>132.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top">
                                    <paragraph>≥18</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>159</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In treprostinil-naïve patients and those transitioning from treprostinil inhalation solution, dose increases of 26.5 mcg per dose each week may be implemented, as tolerated. The target maintenance dosage is 79.5-106 mcg, 4 times daily. Doses above 848 mcg per day have not been studied in patients with PAH.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f5575b63-1e78-4956-9ed2-2ea6da72808f">
               <id root="b291b7c9-5c30-4993-8af6-f33b5e08fb55"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>YUTREPIA inhalation powder contained in capsule available in 4 strengths:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>26.5 mcg: opaque yellow cap and clear body capsule with “LIQUIDIA 26.5” in black radial imprint on capsule cap.</item>
                     <item>
                        <caption>•</caption>53 mcg: opaque green cap and clear body capsule with “LIQUIDIA 53” in white radial imprint on capsule cap.</item>
                     <item>
                        <caption>•</caption>79.5 mcg: opaque blue cap and clear body capsule with “LIQUIDIA 79.5” in white radial imprint on capsule cap.</item>
                     <item>
                        <caption>•</caption>106 mcg: opaque purple cap and clear body capsule with “LIQUIDIA 106” in white radial imprint on capsule cap.</item>
                  </list>
               </text>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>YUTREPIA inhalation powder contained in capsule is available in 4 strengths: 26.5 mcg, 53 mcg, 79.5 mcg, 106 mcg (<linkHtml href="#ID_f5575b63-1e78-4956-9ed2-2ea6da72808f">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_8aff61f5-f59a-40c6-af66-5b6b2c1ca586">
               <id root="60b991d5-5b6b-4a7b-ad3d-8aec0a3c8233"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#ID_8aff61f5-f59a-40c6-af66-5b6b2c1ca586">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_dc068ae2-5fa1-441f-b14b-087a533761ea">
               <id root="ad306dc5-95dd-4f3c-a670-e52c8a36a618"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Treprostinil may cause symptomatic hypotension. (<linkHtml href="#ID_bbc376db-8f42-43b6-afb9-3b7c7d4e61d4">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Treprostinil inhibits platelet aggregation and increases the risk of bleeding. (<linkHtml href="#ID_131904d8-e3b2-461c-9a04-517944be2159">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn. (<linkHtml href="#ID_b2c585d1-2606-4467-98f8-e28f6b16c995">5.3</linkHtml>, <linkHtml href="#ID_14c818df-64cb-4be6-b5b4-ea5365aa0ca4">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>May cause bronchospasm: Patients with a history of hyperreactive airway disease may be more sensitive. (<linkHtml href="#ID_9dac0a22-4b36-4e5b-a299-2fb61e26f4ce">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_bbc376db-8f42-43b6-afb9-3b7c7d4e61d4">
                     <id root="794715c6-27ba-442a-bf77-545e795cd1e6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk of Symptomatic Hypotension </title>
                     <text>
                        <paragraph>Treprostinil is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with treprostinil may produce symptomatic hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_131904d8-e3b2-461c-9a04-517944be2159">
                     <id root="5b27880b-b872-4ebe-893f-a9e92c93cf74"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Risk of Bleeding </title>
                     <text>
                        <paragraph>Treprostinil inhibits platelet aggregation and increases the risk of bleeding.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b2c585d1-2606-4467-98f8-e28f6b16c995">
                     <id root="56aca367-6095-40b2-a6b4-68bfcaaee13c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Effect of Other Drugs on Treprostinil </title>
                     <text>
                        <paragraph>Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both C<sub>max</sub> and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_14c818df-64cb-4be6-b5b4-ea5365aa0ca4">7.1</linkHtml>) and Clinical Pharmacology (<linkHtml href="#ID_39b19811-803e-444e-bc6c-fc1eec545212">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9dac0a22-4b36-4e5b-a299-2fb61e26f4ce">
                     <id root="f55df1e9-36fd-443a-9d1b-5999cfa064ac"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Bronchospasm </title>
                     <text>
                        <paragraph>Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment with YUTREPIA.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9e5e1c52-2ea2-4bd5-b40c-8bff115d3a3a">
               <id root="a4a784b8-3b04-43ae-b1a9-ff032b0a5f4e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following potential adverse reactions are described in Warnings and Precautions (<linkHtml href="#ID_dc068ae2-5fa1-441f-b14b-087a533761ea">5</linkHtml>):</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>-</caption>Decrease in systemic blood pressure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_bbc376db-8f42-43b6-afb9-3b7c7d4e61d4">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption>-</caption>Bleeding <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_131904d8-e3b2-461c-9a04-517944be2159">5.2</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20250523"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions with YUTREPIA (³10%) are cough, headache, throat irritation, and dizziness. (<linkHtml href="#ID_9e5e1c52-2ea2-4bd5-b40c-8bff115d3a3a">6</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Liquidia Technologies, Inc. at 1-888-393-LQDA (5732)</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8d2b2bce-e6cd-4c93-a092-3066cfea20f6">
                     <id root="4f500925-7900-42ad-8246-7f2dd65f5fdb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety and tolerability of YUTREPIA was evaluated in an open label study (INSPIRE) of 121 patients with PAH (WHO Group 1 and NYHA Functional Class II [80 patients] and Class III [41 patients]) followed for up to 2 months. The most commonly reported adverse reactions included cough, headache, throat irritation, dizziness, which are known side effects of treprostinil inhalation solution. <linkHtml href="#_Ref198876291" title="Table 2">Table 2</linkHtml> lists the adverse reactions that occurred at a rate of at least 4% of the overall INSPIRE safety population. The adverse reactions in the INSPIRE study were consistent with those observed in previous studies of inhaled treprostinil.</paragraph>
                        <table ID="_Ref198876291" width="50%" cellpadding="3.6pt">
                           <caption>Table 2: Adverse Reactions Occurring in ≥ 4% of Patients in the INSPIRE Study</caption>
                           <col width="23%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="3">*Transition: Patients were on stable doses of treprostinil inhalation solution for at least 3 months prior to enrollment in the study and transitioned to treatment with YUTREPIA.<br/>†Add-on: Patients were prostacyclin-naïve and were taking no more than 2 approved oral PAH therapies for at least 3 months at time of enrollment and addition of treatment with YUTREPIA.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Transition*<br/>N=55</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Add-On†<br/>N=66</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="bottom" styleCode="Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode="Toprule ">
                                    <paragraph>Cough</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule ">
                                    <paragraph>15 (27)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule ">
                                    <paragraph>36 (55)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (25)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>18 (27)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Throat Irritation</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (9)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>14 (21)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>6 (11)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>7 (11)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (6)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>8 (12)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Chest Discomfort</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (9)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (7)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Dyspnea</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (6)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>3 (5)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Flushing</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>5 (8)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom">
                                    <paragraph>Oropharyngeal Pain</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>1 (2)</paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>4 (6)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3021dd00-2e8d-4a96-ab41-a18c1c0e8ca4">
                     <id root="ed103b9a-6da6-4a54-9e85-27dc51d298cc"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Adverse Reactions Identified in Post-Marketing Experience </title>
                     <text>
                        <paragraph>The following adverse reaction has been identified during the post-approval use of treprostinil inhalation solution. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Angioedema</item>
                        </list>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a414ea81-060a-4f22-bff1-11aafb11fbed">
               <id root="cff49e57-3b11-4314-bd76-3f96ec1b6d7d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="ID_14c818df-64cb-4be6-b5b4-ea5365aa0ca4">
                     <id root="4c4cee4c-f183-461f-b9f2-139e5ff77a51"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Cytochrome P450 Inhibitors and Inducers </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A.</paragraph>
                        <paragraph>Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A.</paragraph>
                        <paragraph>Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both C<sub>max</sub> and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_b2c585d1-2606-4467-98f8-e28f6b16c995">5.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2e4bbfff-eecb-454f-8074-4911e67e5431">
                     <id root="eae22b1c-1998-46d7-abbb-faa3a52a776f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of Other Drugs on Treprostinil </title>
                     <text>
                        <paragraph>Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively, in healthy volunteers. These studies did not show a clinically significant effect on the pharmacokinetics of treprostinil. Treprostinil does not affect the pharmacokinetics or pharmacodynamics of warfarin. The pharmacokinetics of R- and S- warfarin and the INR in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_66198737-8d4f-48bd-a47b-b9a0ce669f41">
               <id root="64dbd6e8-9aae-49f4-b34f-aa96bca9cd73"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="ID_4abd63c2-76fe-49cd-aa4a-fa735ca9f4ad">
                     <id root="2e522eae-597e-4ef0-8f20-5fd22eaa8a5d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20250523"/>
                     <component>
                        <section ID="ID_49c168a9-67f2-411b-b4bf-a5639e64e3d8">
                           <id root="dd96d5f0-766d-4f74-9132-1b44ef50ede2"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="69759-9" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see <content styleCode="italics">
                                    <linkHtml href="#ID_e5ab57fc-59cd-4478-8527-be957122e8b4">Clinical Considerations</linkHtml>
                                 </content>). In animal studies, no adverse reproductive and developmental effects were seen for treprostinil at <sup>3</sup>9 and <sup>3</sup>145 times the human exposure when based on C<sub>max</sub> and AUC, respectively, following a single YUTREPIA dose of 79.5 mcg <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_39b19811-803e-444e-bc6c-fc1eec545212">12.3</linkHtml>)]</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250523"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_e5ab57fc-59cd-4478-8527-be957122e8b4">
                           <id root="c82c711d-6607-43af-8564-0484ce322bc7"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Disease-associated maternal and embryo-fetal risk</content>
                              </paragraph>
                              <paragraph>Pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality.</paragraph>
                           </text>
                           <effectiveTime value="20250523"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_82449277-eb03-4715-b6a1-6af6a6e14cfd">
                           <id root="f0724899-8da8-48f3-9f2c-fbe7c88836b0"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>Animal reproduction studies have been conducted with treprostinil via continuous subcutaneous administration and with treprostinil diolamine administered orally. In studies with orally administered treprostinil diolamine, no adverse effect doses for fetal viability/growth, fetal development (teratogenicity), and postnatal development were determined in rats. In pregnant rats, no evidence of harm to the fetus was observed following oral administration of treprostinil diolamine at the highest dose tested (20 mg/kg/day), which represents about 154 and 1479 times the human exposure, when based on C<sub>max</sub> and AUC, respectively, following a single YUTREPIA dose of 79.5 mcg. In pregnant rabbits, external fetal and soft tissue malformations and fetal skeletal malformation occurred. The dose at which no adverse effects were seen (0.5 mg/kg/day) represents about 9 and 145 times the human exposure, when based on C<sub>max</sub> and AUC, respectively, following a single YUTREPIA dose of 79.5 mcg.  No treprostinil treatment-related effects on labor and delivery were seen in animal studies. Animal reproduction studies are not always predictive of human response.</paragraph>
                           </text>
                           <effectiveTime value="20250523"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_8072df3d-c732-438e-8b8b-879dcdbaf9a0">
                     <id root="b9cc29f1-79ff-4c35-a144-fa80f219235a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20250523"/>
                     <component>
                        <section ID="ID_49b81cd0-b7a1-4313-bf30-85b1b3776108">
                           <id root="50aa5afc-9d00-427b-9300-cb853d339777"/>
                           <code codeSystem="2.16.840.1.113883.6.1" code="69759-9" displayName="RISKS"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                           </text>
                           <effectiveTime value="20250523"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_31086541-5bf6-4a98-b17f-abfefb6ca599">
                     <id root="5dc23d7c-371c-4565-a6e3-b740ee11cc9f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_316a0ed3-0e26-437c-b54e-0e82439f9c69">
                     <id root="f6f1a83b-0439-4e9d-a574-c112062db865"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Placebo-controlled clinical studies of treprostinil inhalation solution did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. The open-label INSPIRE study in PAH patients included 28 patients aged 65 and over in which no age-related differences were noted. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_22139394-6ee4-4901-9142-f2eb275c8b21">
                     <id root="76ad89d4-731d-41bf-bded-ab080405975a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88829-7" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Patients with Hepatic Insufficiency </title>
                     <text>
                        <paragraph>Plasma clearance of treprostinil, delivered subcutaneously, was reduced up to 80% in subjects with mild-to-moderate hepatic insufficiency. Uptitrate slowly when treating patients with hepatic insufficiency because of the risk of an increase in systemic exposure which may lead to an increase in dose-dependent adverse effects. Treprostinil has not been studied in patients with severe hepatic insufficiency <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_39b19811-803e-444e-bc6c-fc1eec545212">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fc4f45f5-5d9b-444d-9302-d7fd584aa6b3">
                     <id root="9dfed16d-a9b4-4a53-8f7e-c81ec2107c44"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88828-9" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Patients with Renal Insufficiency </title>
                     <text>
                        <paragraph>No dose adjustments are required in patients with renal impairment. Treprostinil is not cleared by dialysis <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_39b19811-803e-444e-bc6c-fc1eec545212">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2f0d1563-c421-4b84-a5a6-27b5eec2834b">
               <id root="e30fb661-27c0-4d83-81be-239e56fae736"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>In general, symptoms of overdose with treprostinil include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Provide general supportive care until the symptoms of overdose have resolved.</paragraph>
               </text>
               <effectiveTime value="20250523"/>
            </section>
         </component>
         <component>
            <section ID="ID_649b73d8-b41c-47dd-b083-bd9c72d9642c">
               <id root="28a8b386-9f8b-40ab-be74-2b35aa8e3f31"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>YUTREPIA contains treprostinil sodium, a prostacyclin mimetic.  The chemical name for tresprostinil sodium is 2-{[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H,2H,3H,3aH,4H,9H,9aH-cyclopenta[b]naphthalen-5-yl]oxy}acetic acid, sodium salt with the structural formula:</paragraph>
                  <renderMultiMedia referencedObject="ID_146c6568-aa1f-4931-8996-b5b16d8e4b32" ID="id1432703176"/>
                  <paragraph>Treprostinil sodium has a molecular formula of C<sub>23</sub>H<sub>33</sub>O<sub>5</sub>Na and a molecular weight of 412.49 daltons equivalent to 390.5 daltons of Treprostinil.  </paragraph>
                  <paragraph>YUTREPIA inhalation powder contained in a capsule is intended for oral inhalation. The capsule contains white to off-white powder of treprostinil sodium and the inactive ingredients L-leucine, polysorbate 80, sodium citrate, sodium chloride, and trehalose. Each 5 mg of  YUTREPIA inhalation powder contains 26.5 mcg of treprostinil, where 26.5 mcg of treprostinil is equivalent to 28 mcg of treprostinil sodium. </paragraph>
                  <paragraph>The accompanying inhalation device for delivery of YUTREPIA inhalation powder is a disposable plastic device used to inhale the dry powder contained in the HPMC capsule. </paragraph>
                  <paragraph>The amount of drug delivered to the lungs will vary depending on patient factors such as inspiratory flow and peak inspiratory flow through the inhalation device, which may vary from patient to patient. </paragraph>
                  <paragraph>Under standardized <content styleCode="italics">in vitro</content> testing, the inhalation device delivers the following amounts of treprostinil for each of the YUTREPIA inhalation powder capsule strengths:  </paragraph>
                  <paragraph>
                     <content styleCode="bold">YUTREPIA Inhalation Powder Delivered Dose</content>
                  </paragraph>
                  <table width="50%" cellpadding="3.6pt">
                     <col width="28%"/>
                     <col width="28%"/>
                     <tfoot>
                        <tr>
                           <td align="left" valign="top" colspan="2">
                              <sup>a </sup>Amount of treprostinil delivered from the device mouthpiece under an <content styleCode="italics">in vitro</content> flow rate of 99 L/min with a collection time of 1.2 seconds (2 L total volume).</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle" styleCode="Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Capsule Strength <br/>(treprostinil)</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="middle" styleCode="Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Dose Delivered <sup>a</sup>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Toprule ">
                              <paragraph>26.5 mcg</paragraph>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule ">
                              <paragraph>15.1 mcg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>53 mcg</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>36.0 mcg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>79.5 mcg</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>56.6 mcg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <paragraph>106 mcg</paragraph>
                           </td>
                           <td align="center" valign="middle">
                              <paragraph>75.7 mcg</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250523"/>
               <component>
                  <observationMedia ID="ID_146c6568-aa1f-4931-8996-b5b16d8e4b32">
                     <text>Structural Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_12eb500a-0da9-4cbb-9c6d-a1c33eb31a61">
               <id root="adb1b8cd-061d-40cb-a52f-ca49d558147d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="ID_31c43218-8440-40d4-bc1e-60988cfde192">
                     <id root="792d281c-88af-4e5c-a397-6177c1bc85d0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d0315589-7d16-4b62-adc9-2180a4989401">
                     <id root="6d149697-0744-4917-87f6-387f8b5a2e83"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. Other studies have shown that treprostinil causes a dose-related negative inotropic and lusitropic effect. No major effects on cardiac conduction have been observed. Treprostinil produces vasodilation and tachycardia. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>In a clinical trial of 240 healthy volunteers, single doses of treprostinil inhalation solution 54 mcg (the target maintenance dose per session) and 84 mcg (supratherapeutic inhalation dose) prolonged the corrected QTc interval by approximately 10 ms. The QTc effect dissipated rapidly as the concentration of treprostinil decreased.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_39b19811-803e-444e-bc6c-fc1eec545212">
                     <id root="291e2b91-37d0-4c16-bce2-ed5894a9c762"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption </content>
                        </paragraph>
                        <paragraph>In healthy volunteer studies, the systemic exposure (AUC and C<sub>max</sub>) post-inhalation was shown to be proportional to the YUTREPIA doses administered (25 mcg – 150 mcg). The treprostinil mean C<sub>max</sub>, mean AUC<sub>inf</sub> and median T<sub>max</sub> following a single inhaled target maintenance dose of 79.5 mcg YUTREPIA were 1.48 ng/mL, 1.04 hr.ng/mL and 0.13 hr, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> treprostinil is 91% bound to human plasma proteins over the 330-10,000 ng/mL concentration range.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism and Excretion</content>
                        </paragraph>
                        <paragraph>Of subcutaneously administered treprostinil, only 4% is excreted unchanged in urine. Treprostinil is substantially metabolized by the liver, primarily by CYP2C8. Metabolites are excreted in urine (79%) and feces (13%) over 10 days. Five apparently inactive metabolites were detected in the urine, each accounting for 10‑15% of the dose administered. Four of the metabolites are products of oxidation of the 3-hydroxyloctyl side chain and one is a glucuroconjugated derivative (treprostinil glucuronide).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Following inhaled administration of YUTREPIA, disposition and elimination is monophasic with a half-life of approximately 30 minutes. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Insufficiency</content>
                        </paragraph>
                        <paragraph>Plasma clearance of treprostinil, delivered subcutaneously, was reduced up to 80% in subjects presenting with mild-to-moderate hepatic insufficiency. Treprostinil has not been studied in patients with severe hepatic insufficiency <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_22139394-6ee4-4901-9142-f2eb275c8b21">8.6</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Insufficiency</content>
                        </paragraph>
                        <paragraph>In patients with severe renal impairment requiring dialysis (n=8), administration of a single 1 mg dose of orally administered treprostinil pre-and post-dialysis resulted in AUC0-inf that was not significantly altered compared to healthy subjects <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_fc4f45f5-5d9b-444d-9302-d7fd584aa6b3">8.7</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6c70a5b3-437c-43c1-88e0-d00a1ced864b">
               <id root="e0eb984a-b12d-4089-98e1-15dcfff13035"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="ID_e0b75cf1-a9aa-40e8-9af7-d2821e720595">
                     <id root="c38523f5-3d57-419e-9e85-761c3beb9042"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>A two-year rat carcinogenicity study was performed with treprostinil inhalation solution at target treprostinil doses of 5.26, 10.6, and 34.1 µg/kg/day. There was no evidence for carcinogenic potential associated with treprostinil inhalation in rats at systemic exposure levels up to 35 times following a single YUTREPIA dose of 79.5 mcg <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_39b19811-803e-444e-bc6c-fc1eec545212">12.3</linkHtml>)]</content>. <content styleCode="italics">In vitro</content> and <content styleCode="italics">in vivo</content> genetic toxicology studies did not demonstrate any mutagenic or clastogenic effects of treprostinil. Treprostinil sodium did not affect fertility or mating performance of male or female rats given continuous subcutaneous (sc) infusions at rates of up to 450 ng treprostinil/kg/min. In this study, males were dosed from 10 weeks prior to mating and through the 2-week mating period. Females were dosed from 2 weeks prior to mating until gestational day 6.</paragraph>
                        <paragraph>Oral administration of treprostinil diolamine to Tg.rasH2 mice at 0, 5, 10 and 20 mg/kg/day in males and 0, 3, 7.5 and 15 mg/kg/day in females daily for 26 weeks did not significantly increase the incidence of tumors.</paragraph>
                        <paragraph>Treprostinil diolamine was tested <content styleCode="italics">in vivo</content> in a rat micronucleus assay and did not induce an increased incidence of micronucleated polychromatic erythrocytes.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_13242058-3eab-4e27-b83b-708500623272">
                     <id root="e7fbb446-6ccd-4b2b-8d53-7c3a6eac7949"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34091-9" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology </title>
                     <text>
                        <paragraph>In a 2-year rat study with treprostinil inhalation at target doses of 5.26, 10.6, and 34.1 mcg/kg/day, there were more deaths (11) in the mid- and high-dose treprostinil groups during the first 9 weeks of the study, compared to 1 in control groups. At the high-dose level, males showed a higher incidence of inflammation in teeth and preputial gland, and females showed high incidences of inflammation and urothelial hyperplasia in the urinary bladder. The exposures in rats at mid- and high-dose levels were about 15 and 35 times, respectively, the clinical exposure following a single YUTREPIA dose of 79.5 mcg <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_39b19811-803e-444e-bc6c-fc1eec545212">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250523"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_127d9518-e71f-47d6-b341-8889ffa0f6a2">
               <id root="c84ca225-50bb-4bc8-a80f-887ed55d4cdf"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20250523"/>
               <component>
                  <section ID="ID_894a47d0-a9c1-4f96-b5b4-25744ac45a8c">
                     <id root="07c3559d-a5c3-467d-9181-357b6ac7821d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Pulmonary Arterial Hypertension (WHO Group 1) </title>
                     <text>
                        <paragraph>TRIUMPH I was a 12-week, randomized, double-blind, placebo-controlled multi-center study of patients with PAH. The study population included 235 clinically stable patients with pulmonary arterial hypertension (WHO Group 1), nearly all with NYHA Class III (98%) symptoms who were receiving either bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase-5 inhibitor) for at least three months prior to study initiation. Concomitant therapy also could have included anticoagulants, other vasodilators (e.g., calcium channel blockers), diuretics, oxygen, and digitalis, but not a prostacyclin. These patients were administered either placebo or treprostinil inhalation solution in four daily treatment sessions with a target dose of 9 breaths (equivalent to 79.5 mcg YUTREPIA) per session over the course of the 12-week study. Patients were predominantly female (82%), had the origin of PAH as idiopathic/heritable (56%), secondary to connective tissue diseases (33%) or secondary to HIV or previous use of anorexigens (12%); bosentan was the concomitant oral medication in 70% of those enrolled, sildenafil in 30%.</paragraph>
                        <paragraph>The primary efficacy endpoint of the trial was the change in six-minute walk distance (6MWD) relative to baseline at 12 weeks. 6MWD was measured at peak exposure (between 10 and 60 minutes after dosing), and 3‑5 hours after bosentan or 0.5-2 hours after sildenafil. Patients receiving treprostinil inhalation solution had a placebo-corrected median change from baseline in peak 6MWD of 20 meters at Week 12 (p&lt;0.001).</paragraph>
                        <paragraph>The distribution of these 6MWD changes from baseline at Week 12 were plotted across the range of observed values (<linkHtml href="#id1045497769" title="Figure 1">Figure 1</linkHtml>). 6MWD measured at trough exposure (defined as measurement of 6MWD at least 4 hours after dosing) improved by 14 meters. There were no placebo-controlled 6MWD assessments made after 12 weeks.</paragraph>
                        <renderMultiMedia referencedObject="F0F1DE7C-64DF-4464-8BAC-80966234F839" ID="id1045497769">
                           <caption>Figure 1. Distributions of 6MWD Changes from Baseline at Week 12 during Peak Plasma Concentration of Treprostinil Inhalation Solution</caption>
                        </renderMultiMedia>
                        <paragraph>The placebo-corrected median treatment effect on 6MWD was estimated (using the Hodges-Lehmann estimator) within various subpopulations defined by age quartile, gender, geographic region of the study site, disease etiology, baseline 6MWD quartile, and type of background therapy (<linkHtml href="#id1760252981" title="Figure 2">Figure 2</linkHtml>).</paragraph>
                        <renderMultiMedia referencedObject="ID_89c8682d-b4b2-41d7-9bd4-f05d851eb684" ID="id1760252981">
                           <caption>Figure 2. Placebo-Corrected Median Treatment Effect (Hodges-Lehmann estimate with 95% CI) on 6MWD Change from Baseline at Week 12 During Peak Plasma Concentration of Treprostinil Inhalation Solution for Various Subgroups</caption>
                        </renderMultiMedia>
                     </text>
                     <effectiveTime value="20250523"/>
                     <component>
                        <observationMedia ID="F0F1DE7C-64DF-4464-8BAC-80966234F839">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_89c8682d-b4b2-41d7-9bd4-f05d851eb684">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_55bc5520-e509-48d0-9d25-58a93adc2014">
                     <id root="bb0dbda5-5988-4233-ace1-dd07ee0567e3"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Pulmonary Hypertension Associated with ILD (WHO Group 3) </title>
                     <text>
                        <paragraph>INCREASE was a 16-week, randomized, double-blind, placebo-controlled, multicenter study that enrolled 326 patients with PH-ILD. Enrolled study patients predominately had etiologies of idiopathic interstitial pneumonia (45%) inclusive of idiopathic pulmonary fibrosis, combined pulmonary fibrosis and emphysema (25%), and WHO Group 3 connective tissue disease (22%). The mean baseline 6MWD was 260 meters.</paragraph>
                        <paragraph>Patients in the INCREASE study were randomized (1:1) to either placebo or treprostinil inhalation solution in four daily treatment sessions with a target dose of 9 breaths (equivalent to 79.5 mcg YUTREPIA) per session and a maximum dose of 12 breaths (equivalent to 106 mcg YUTREPIA) per session over the course of the 16-week study. Approximately 75% of patients randomized to treprostinil inhalation solution titrated up to a dose of 9 breaths, 4 times daily or greater, with 48% of patients randomized to  treprostinil inhalation solution reaching a dose of 12 breaths, 4 times daily during the study. The primary efficacy endpoint was the change in 6MWD measured at peak exposure (between 10 and 60 minutes after dosing) from baseline to Week 16. Patients receiving  treprostinil inhalation solution had a placebo-corrected median change from baseline in peak 6MWD of 21 meters at Week 16 (p=0.004) using Hodges-Lehmann estimate (<linkHtml href="#id277771541" title="Figure 3">Figure 3</linkHtml>).</paragraph>
                        <renderMultiMedia referencedObject="ID_67ce5fd2-ebcb-4be2-981b-4e46979a054f" ID="id277771541">
                           <caption>Figure 3: Hodges-Lehmann Estimate of Treatment Effect by Visit for 6MWD at Peak Exposure (PH-ILD)</caption>
                        </renderMultiMedia>
                        <paragraph>The treatment effect on 6MWD at Week 16 was consistent for various subgroups, including etiology of PH-ILD, disease severity, age, sex, baseline hemodynamics, and dose (<linkHtml href="#id-558632146" title="Figure 4">Figure 4</linkHtml>).</paragraph>
                        <renderMultiMedia referencedObject="ID_12162d0f-7f9b-4ac6-b66b-9ee4b946842b" ID="id-558632146">
                           <caption>Figure 4: Forest Plot on Subgroup Analyses of Peak 6MWD (Meter) at Week 16 (PH-ILD)</caption>
                        </renderMultiMedia>
                        <paragraph>Time to clinical worsening in the INCREASE study was defined as the time of randomization until 1 of the following criteria were met: hospitalization due to a cardiopulmonary indication, decrease in 6MWD &gt;15% from baseline directly related to PH-ILD at 2 consecutive visits and at least 24 hours apart, death (all causes), or lung transplantation. Treatment with treprostinil inhalation solution in patients with PH-ILD resulted in numerically fewer hospitalizations. The numbers of reported deaths were the same for both treatment groups (<linkHtml href="#_Ref198877000" title="Table 3">Table 3</linkHtml>). Overall, treatment with treprostinil inhalation solution demonstrated a statistically significant increase in the time to first clinical worsening event (log-rank test p=0.041; <linkHtml href="#id-337389362" title="Figure 5">Figure 5</linkHtml>), and a 39% overall reduction in the risk of a clinical worsening event (HR=0.61 [95% CI; 0.40, 0.92]; <linkHtml href="#id-337389362" title="Figure 5">Figure 5</linkHtml>).</paragraph>
                        <table ID="_Ref198877000" width="100%" cellpadding="3.6pt">
                           <caption>Table 3: Clinical Worsening Events (PH-ILD)</caption>
                           <col width="14%"/>
                           <col width="39%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <col width="16%"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Botrule Lrule Toprule "/>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Tyvaso<br/>n=163<br/>n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Placebo<br/>n=163<br/>n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">HR (95% CI)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Clinical worsening</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>37 (22.7%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>54 (33.1%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>0.61 (0.40, 0.92)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="4" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">First contributing event</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Hospitalization due to a cardiopulmonary indication</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>18 (11.0%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>24 (14.7%)</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Decrease in 6MWD &gt; 15% from baseline directly related to PH-ILD</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>13 (8.0%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>26 (16.0%)</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Death (all causes)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>4 (2.5%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>4 (2.5%)</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Lung transplantation</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>2 (1.2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Toprule Botrule ">
                                    <paragraph> </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold"> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold"> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold"> </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Tyvaso<br/>n=163<br/>n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Placebo<br/>n=163<br/>n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">HR (95% CI)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="4" valign="top" styleCode="Rrule Lrule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">First of each event</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Hospitalization due to a cardiopulmonary indication</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>21 (12.9)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>30 (18.4%)</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Decrease in 6MWD &gt; 15% from baseline directly related to PH-ILD</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>16 (9.8%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>31 (19.0%)</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>
                                       <content styleCode="bold">Death (all causes)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>8 (4.9%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                                    <paragraph>10 (6.1%)</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Lrule Toprule Botrule "/>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>
                                       <content styleCode="bold">Lung transplantation</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>2 (1.2%)</paragraph>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                                    <paragraph>1 (0.6%)</paragraph>
                                 </td>
                                 <td valign="top" styleCode="Rrule Botrule Lrule Toprule "/>
                              </tr>
                           </tbody>
                        </table>
                        <renderMultiMedia referencedObject="D5B997E3-B156-45FA-BF97-50CFAE526232" ID="id-337389362">
                           <caption>Figure 5: Kaplan-Meier Plot of Time to Clinical Worsening Events (PH-ILD)</caption>
                        </renderMultiMedia>
                     </text>
                     <effectiveTime value="20250523"/>
                     <component>
                        <observationMedia ID="ID_67ce5fd2-ebcb-4be2-981b-4e46979a054f">
                           <text>Figure 3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_12162d0f-7f9b-4ac6-b66b-9ee4b946842b">
                           <text>Figure 4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="D5B997E3-B156-45FA-BF97-50CFAE526232">
                           <text>Figure 5</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-06.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d8cb4ba6-3f19-46ab-8c09-feee35068fec">
               <id root="f26eb7b9-2124-404f-8743-f47d61440e16"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>YUTREPIA is supplied in a carton consisting of 1 capsule based, dry powder inhaler (referred to as “inhaler”), 28 capsules (7 foil blister cards of 4 capsules each), and 7 single-use cleaning brushes. The individual capsule well is connected by an air channel to a separate blister well containing a desiccant strip.  Descriptions of YUTREPIA carton by capsule strength are provided in <linkHtml href="#_Ref198877048" title="Table 4">Table 4</linkHtml> below:</paragraph>
                  <table ID="_Ref198877048" width="75%" cellpadding="3.6pt">
                     <caption>Table 4: YUTREPIA Carton Contents by Capsule Strength</caption>
                     <col width="23%"/>
                     <col width="39%"/>
                     <col width="23%"/>
                     <thead>
                        <tr>
                           <th valign="middle" align="center" styleCode="Botrule ">Capsule Strength<br/>(mcg treprostinil)</th>
                           <th valign="middle" align="center" styleCode="Botrule ">Capsule Description</th>
                           <th valign="middle" align="center" styleCode="Botrule ">NDC Number</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>26.5</paragraph>
                           </td>
                           <td valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>Opaque yellow cap, clear body, imprinted with “LIQUIDIA 26.5” in black ink radially on cap</paragraph>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>72964-011-01</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>53</paragraph>
                           </td>
                           <td valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>Opaque green cap, clear body, imprinted with “LIQUIDIA 53” in white ink radially on cap</paragraph>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>72964-012-01</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>79.5</paragraph>
                           </td>
                           <td valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>Opaque blue cap, clear body, imprinted with “LIQUIDIA 79.5” in white ink radially on cap</paragraph>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule Botrule ">
                              <paragraph>72964-013-01</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle" styleCode="Toprule ">
                              <paragraph>106</paragraph>
                           </td>
                           <td valign="middle" styleCode="Toprule ">
                              <paragraph>Opaque purple cap, clear body, imprinted with “LIQUIDIA 106” in white ink radially on cap</paragraph>
                           </td>
                           <td align="center" valign="middle" styleCode="Toprule ">
                              <paragraph>72964-014-01</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>YUTREPIA inhalation powder capsules should only be delivered using the capsule-based inhaler. The off-white plastic inhaler consists of a blue protective cap marked with YUTREPIA and a base with a mouthpiece, capsule chamber, and two blue push buttons. Discard the inhaler device after 7 days of use or 56 actuations, whichever comes first.</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Capsules should remain in the blister to protect them from moisture and light, and each capsule should be removed only when ready to administer a dose.</paragraph>
                  <paragraph>Keep out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20250523"/>
            </section>
         </component>
         <component>
            <section ID="ID_a6e8f3f5-6cbc-4533-ab43-e356f28fbba5">
               <id root="d18cc260-311d-40e5-a7bc-e9465821e5b3"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Instructions for Use).</paragraph>
                  <paragraph>Train patients in the administration process for YUTREPIA, including dosing, inhaler preparation, administration, cleaning, and maintenance, according to the instructions for use <content styleCode="italics">[see <linkHtml href="#ID_4b9facf4-f433-465f-9de2-2f941333c2f6">Instructions for Use</linkHtml>]</content>.</paragraph>
                  <paragraph>To avoid potential interruptions in drug delivery because of equipment malfunction, patients should have access to a back-up.  </paragraph>
                  <paragraph>In the event that a scheduled dose is missed, take another dose as soon as possible. </paragraph>
                  <paragraph>
                     <sup>®</sup>Copyright 2022 Liquidia Technologies, Inc. All rights reserved. </paragraph>
                  <paragraph>Distributed by: Liquidia Technologies, Inc. Morrisville, NC 27560</paragraph>
               </text>
               <effectiveTime value="20250523"/>
            </section>
         </component>
         <component>
            <section ID="ID_4b9facf4-f433-465f-9de2-2f941333c2f6">
               <id root="e977b587-1bab-4b64-8a64-a2b29f1c6b0f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">YUTREPIA<sup>TM</sup> (you-TREP-ee-uh)<br/>(treprostinil)<br/>inhalation powder, for oral inhalation</content>
                  </paragraph>
                  <paragraph>This Instructions for Use contains information on how to inhale YUTREPIA<sup>TM</sup>. Read these Instructions for Use before you start using YUTREPIA and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Your healthcare provider should show you or your caregiver how to use YUTREPIA the right way before you use it for the first time.</content>
                  </paragraph>
                  <table width="75%" styleCode="Noautorules">
                     <col width="85%"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">Important information you need to know before inhaling YUTREPIA inhalation powder:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> swallow YUTREPIA capsules. YUTREPIA is for inhalation only.</item>
                                 <item>
                                    <caption>•</caption>Use YUTREPIA as prescribed by your healthcare provider.</item>
                                 <item>
                                    <caption>•</caption>YUTREPIA capsules come in 4 strengths: 26.5 mcg, 53 mcg, 79.5 mcg, and 106 mcg.</item>
                                 <item>
                                    <caption>•</caption>If your prescribed dose is more than 106 mcg, you will need to inhale 2 YUTREPIA capsules. <content styleCode="bold">See Figure C</content>: Dosing Chart to help you identify the 2 capsules needed for your prescribed dose. Only use the capsule combinations in the Dosing Chart when your prescribed dose is more than 106 mcg.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">The capsule must be inhaled within 5 minutes of opening the blister card or the full dose may not be administered. Read through this instruction sheet prior to the first use of this product. </content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Always inhale each capsule 2 times to make sure you get your full dose of YUTREPIA.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Do not</content> wash the inhaler. Keep the inhaler dry.</item>
                                 <item>
                                    <caption>•</caption>Wash and dry your hands before using YUTREPIA.</item>
                                 <item>
                                    <caption>•</caption>If the contents of the capsule comes in contact with your skin or eyes, rinse the area immediately with water. </item>
                                 <item>
                                    <caption>•</caption>YUTREPIA capsules should remain in the blister card(s) and each capsule should be removed only when ready to deliver a dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">Storing YUTREPIA</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store YUTREPIA carton in a clean, dry place at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>
                                    <caption>•</caption>Leave YUTREPIA capsules in blister card to protect from moisture and light<content styleCode="bold">. </content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Throw away the inhaler after 7 days of use or 56 capsules whichever comes first<content styleCode="bold">.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Keep YUTREPIA and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="75%">
                     <col width="40%"/>
                     <col width="45%"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">Text</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">Illustration</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Get to know YUTREPIA</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>The YUTREPIA carton contains (See Figure A):</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>1 dry powder inhaler (called “inhaler” in these instructions)</item>
                                 <item>
                                    <caption>•</caption>7 Foil blister cards of YUTREPIA capsules (called “capsules” in these instructions) containing 4 capsules each, in one of 4 available strengths</item>
                                 <item>
                                    <caption>•</caption>7 Cleaning brushes (1 for each day)</item>
                                 <item>
                                    <caption>•</caption>1 Desiccant tab within each blister strip to keep the capsule dry and prevent moisture. Throw away the blister strip and the desiccant tab after removing the capsule.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_34498323-a231-4ccf-8baf-a0c8bb93c6f4" ID="id-249888560"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Preparing to use YUTREPIA</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">The capsule must be inhaled within 5 minutes of opening the blister card. Ensure all supplies are gathered and you are familiar with the use of the product prior to opening the card. <br/>
                                    <br/>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">STEP 1. Gather your supplies.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Place your YUTREPIA carton on a clean, dry surface.</item>
                                 <item>
                                    <caption>b.</caption>Remove the inhaler and foil blister cards from the carton <content styleCode="bold">(See Figure B)</content>.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_99496412-9bcd-4fed-9796-e3d53d90d648" ID="id1522194836"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 2. Select the capsule(s) for your dose.</content>
                              </paragraph>
                              <paragraph>Use the Dosing Chart <content styleCode="bold">(See</content>
                                 <content styleCode="bold"> Figure C)</content> to help you identify the capsule(s) needed for your prescribed dose.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>If your prescribed dose is more than 106 mcg, you will need to inhale 2 capsules per the Dosing Chart (see Figure C).</item>
                                 <item>
                                    <caption>•</caption>Only load and inhale 1 capsule at a time.</item>
                                 <item>
                                    <caption>•</caption>All capsules in a carton are the same strength. If your prescribed dose requires 2 capsules of different strengths, you will need to select your capsules from 2 separate cartons.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">IMPORTANT: </content>For doses requiring 2 capsules, only use the capsule combinations presented in the Dosing Chart above <content styleCode="bold">(See Figure C)</content>. The order for inhaling 2 capsules does not matter, regardless of capsule strength.</paragraph>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_0cbca7e1-59db-42f1-b262-2c3fe3e6408e" ID="id-1631008583"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 3. Check the inhaler and blister card(s).</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Look at the inhaler and blister card(s) to make sure they are not damaged <content styleCode="bold">(See Figure D)</content>.<br/>
                                    <content styleCode="bold">Do not </content>use the inhaler or capsules if they are damaged.</item>
                                 <item>
                                    <caption>b.</caption>Look at the expiration date on the blister cards to make sure it has not passed <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure E)</content>.<br/>
                                    <content styleCode="bold">Do not </content>use the capsules if the expiration date has passed.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_7916ed71-67ae-48ed-bffb-8d61ae365635" ID="id-1979369852"/>
                              <renderMultiMedia referencedObject="ID_899cc90a-9e57-4f7a-827e-8bd01d91c80e" ID="id81199609"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Loading YUTREPIA</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 4. Open the inhaler.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Pull the cover straight off the inhaler <content styleCode="bold">(See Figure F)</content>.</item>
                                 <item>
                                    <caption>b.</caption>Rotate the mouthpiece in the direction of the arrow (counter-clockwise) to open the inhaler and expose the capsule chamber <content styleCode="bold">(See Figure G)</content>.<br/>If the mouthpiece separates from the base of the inhaler, gently reattach the 2 pieces and continue to follow the instructions.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_9a61fc5e-93ab-4d7f-b0be-67d0e1302765" ID="id1173217104"/>
                              <renderMultiMedia referencedObject="ID_9ba7d97b-d813-4bde-b170-ea5a5cc631c2" ID="id-1938826607"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 5. Remove the capsule from the blister strip.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Separate 1 blister strip by tearing at the pre-cut lines <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure H)</content>.<br/>
                                    <content styleCode="bold">Do not</content> remove a capsule from the blister strip until you are ready to deliver your dose.</item>
                                 <item>
                                    <caption>b.</caption>Peel the foil away from the blister strip, remove the capsule <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure I)</content>.<br/>
                                    <content styleCode="bold">Do not</content> swallow the capsule.<br/>
                                    <content styleCode="bold">Do not</content> push the capsule through the foil.<br/>
                                    <content styleCode="bold">Do not</content> remove the desiccant tab.<br/>
                                    <content styleCode="bold">Capsule</content> must be used <content styleCode="bold">within 5 minutes</content> of opening the blister card.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_553c5be5-dde8-4656-99e6-0bf698f8db50" ID="id-1831508194"/>
                              <renderMultiMedia referencedObject="DF5EA20D-CC91-4360-856C-38403DCBE9B6" ID="id1071696286"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 6. Secure the capsule in the inhaler.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Hold the inhaler in an upright position.</item>
                                 <item>
                                    <caption>b.</caption>Place the capsule in the capsule chamber in the base of the inhaler <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure J)</content>. Only load 1 capsule.<br/>
                                    <content styleCode="bold">Do not</content> place a capsule in the mouthpiece.<br/>
                                    <content styleCode="bold">Do not</content> swallow capsules.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_46319f3c-bac7-495c-9e4d-152f9ce417a7" ID="id769504993"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 7. Puncture the capsule.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Put one finger on top of the capsule to hold it down <content styleCode="bold">(See Figure</content>
                                    <content styleCode="bold"> K)</content>.</item>
                                 <item>
                                    <caption>b.</caption>While still holding down the capsule, firmly press both puncture buttons all the way in with your other hand <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure L).<br/>
                                    </content>Then let go of (release) the puncture buttons.<br/>This will puncture the capsule. You only need to press the puncture buttons 1 time.</item>
                                 <item>
                                    <caption>c.</caption>Hold the base of the inhaler and<br/>rotate the mouthpiece to close it.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_599de950-905f-47c0-94a2-47f43b4409ea" ID="id2008095826"/>
                              <renderMultiMedia referencedObject="ID_4c998e20-4a50-4a4e-b6ee-d508aacf74de" ID="id971644441"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Inhaling YUTREPIA</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 8. Position the inhaler.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Hold the inhaler upright and away from your mouth. <content styleCode="bold">(See Figure M)</content>.<br/>
                                    <content styleCode="bold">Do not</content> hold the inhaler by the puncture buttons.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="A7CA4DCC-DFF0-4940-9F24-2BBF05A97767" ID="id-1700699378"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 9. Breathe out (exhale).</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Breathe out fully and away from the inhaler <content styleCode="bold">(See Figure N)</content>.<br/>
                                    <content styleCode="bold">Do not</content> exhale into the mouthpiece.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="AF1A5D33-3A56-4CB9-B522-D9232B2B0815" ID="id647180661"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 10. Breathe in deeply (inhale)</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Close your lips around the mouthpiece <content styleCode="bold">(See Figure O)</content>.</item>
                                 <item>
                                    <caption>b.</caption>Tilt your head back slightly <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure O)</content>.</item>
                                 <item>
                                    <caption>c.</caption>Take a comfortable deep breath in (inhale) until your lungs feel full <content styleCode="bold">(See Figure O)</content>.<br/>As you inhale, you will hear or feel a whirring noise as the capsule spins and releases medicine.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="FAEE0B13-CCCB-489F-8988-0281544C9487" ID="id1426691679"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 11. Hold breath, then breathe out (exhale).</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Take the inhaler out of your mouth and hold your breath for 5 seconds or as long as you comfortably can <content styleCode="bold">(See Figure P)</content>.</item>
                                 <item>
                                    <caption>b.</caption>Then breathe out normally.<br/>
                                    <br/>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">IMPORTANT: </content>If you cough when inhaling, repeat STEP 8 through11.</paragraph>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_18405735-c9c5-4ed8-b933-de13ba38ff9f" ID="id-838308560"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 12. Inhale again.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>To make sure the capsule is completely emptied of medicine, repeat STEP 8 through11 <content styleCode="bold">(See Figure Q)</content>.<br/>Always inhale each capsule 2 times to make sure you get your full dose.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_91d0c551-752c-49b1-96de-68a25c7da6f8" ID="id624735993"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Removing and disposing of the capsule</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 13. Open the inhaler.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Rotate the mouthpiece in the direction of the arrow (counter-clockwise) to open the inhaler and expose the capsule chamber <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure R)</content>.</item>
                                 <item>
                                    <caption>b.</caption>Remove the used (empty) capsule and throw away (dispose of) into household trash <content styleCode="bold">(See Figure S)</content>.</item>
                                 <item>
                                    <caption>c.</caption>See box below if you need to use more than 1 capsule to complete your prescribed dose.</item>
                                 <item>
                                    <caption>d.</caption>Continue to Step 14 if you have completed your prescribed dose.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="A0741255-B469-4B11-A520-55E6DD960CD3" ID="id382986315"/>
                              <renderMultiMedia referencedObject="ID_598f630e-7f5e-45ad-a176-7213c7495627" ID="id-37980083"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="center" valign="top" styleCode="Rrule Lrule Botrule ">
                              <renderMultiMedia referencedObject="DD310E83-887F-4B4B-B431-787AF291D668" ID="id1164437088"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Closing and storing the inhaler</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">STEP 14. Close the inhaler.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Hold the base of the inhaler and rotate the mouthpiece to close it <content styleCode="bold">(See Figure T).</content>
                                 </item>
                                 <item>
                                    <caption>b.</caption>Put the cover on the inhaler <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure U)</content>.</item>
                                 <item>
                                    <caption>c.</caption>Store the inhaler in a clean, dry place at room temperature.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_5cd07a84-aee1-4fdf-8633-e47fdc106cc2" ID="id-1167627174"/>
                              <renderMultiMedia referencedObject="DC91B2D7-BD3C-4DE1-B9B0-8E0DEBA4B91B" ID="id498464218"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Cleaning the inhaler (at end of each day)</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Clean the outside and inside of the inhaler after your last dose of the day.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>Wipe the mouthpiece with a dry paper towel, tissue, or clean dry cloth <content styleCode="bold">(See Figure V)</content>.</item>
                                 <item>
                                    <caption>b.</caption>Use the cleaning brush provided to clean the capsule chamber in order to remove visible powder buildup <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure W)</content>.<br/>
                                    <content styleCode="bold">NOTE: </content>Throw away the brush after cleaning. Use only 1 brush each day.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Lrule Toprule Botrule ">
                              <renderMultiMedia referencedObject="ID_973e85ca-1fb6-45e4-b8a4-292ab079e5d3" ID="id1144784693"/>
                              <renderMultiMedia referencedObject="D4388922-BA52-44DF-8290-6CFAE0948335" ID="id1057275343"/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule ">
                              <paragraph>
                                 <content styleCode="bold">Disposing of the inhaler</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Rrule Toprule Botrule "/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <paragraph>
                                 <content styleCode="bold">Throw away (dispose of) the inhaler into household trash after 7 days of use.</content>
                              </paragraph>
                              <list listType="ordered">
                                 <item>
                                    <caption>a.</caption>The inhaler is reusable and will last for 7 days (1 week) or 56 capsules, whichever comes first.  <br/>
                                    <content styleCode="bold">(See</content>
                                    <content styleCode="bold"> Figure X)</content>.</item>
                              </list>
                           </td>
                           <td align="center" valign="top" styleCode="Rrule Botrule Lrule Toprule ">
                              <renderMultiMedia referencedObject="ID_490fdb69-7af3-4aef-b7f1-829c5c2bc3c9" ID="id1232968708"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <sup>®</sup>Copyright 2022 Liquidia Technologies, Inc. All rights reserved. <br/>Distributed by: Liquidia Technologies, Inc. Morrisville, NC 27560<br/>For more information call 1-888-393-LQDA (5732) or go to www.YUTREPIA.com</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration  </paragraph>
                  <paragraph>Issued: May 2025</paragraph>
               </text>
               <effectiveTime value="20250523"/>
               <component>
                  <observationMedia ID="ID_34498323-a231-4ccf-8baf-a0c8bb93c6f4">
                     <text>Figure A - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_99496412-9bcd-4fed-9796-e3d53d90d648">
                     <text>Figure B - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_0cbca7e1-59db-42f1-b262-2c3fe3e6408e">
                     <text>Figure C - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_7916ed71-67ae-48ed-bffb-8d61ae365635">
                     <text>Figure D - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_899cc90a-9e57-4f7a-827e-8bd01d91c80e">
                     <text>Figure E - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_9a61fc5e-93ab-4d7f-b0be-67d0e1302765">
                     <text>Figure F - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_9ba7d97b-d813-4bde-b170-ea5a5cc631c2">
                     <text>Figure G - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_553c5be5-dde8-4656-99e6-0bf698f8db50">
                     <text>Figure H - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DF5EA20D-CC91-4360-856C-38403DCBE9B6">
                     <text>Figure i - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_46319f3c-bac7-495c-9e4d-152f9ce417a7">
                     <text>Figure J - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_599de950-905f-47c0-94a2-47f43b4409ea">
                     <text>Figure K - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_4c998e20-4a50-4a4e-b6ee-d508aacf74de">
                     <text>Figure L - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="A7CA4DCC-DFF0-4940-9F24-2BBF05A97767">
                     <text>Figure M - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="AF1A5D33-3A56-4CB9-B522-D9232B2B0815">
                     <text>Figure N - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-20.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="FAEE0B13-CCCB-489F-8988-0281544C9487">
                     <text>Figure O - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-21.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_18405735-c9c5-4ed8-b933-de13ba38ff9f">
                     <text>Figure P - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-22.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_91d0c551-752c-49b1-96de-68a25c7da6f8">
                     <text>Figure Q - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-23.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="A0741255-B469-4B11-A520-55E6DD960CD3">
                     <text>Figure R - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-24.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_598f630e-7f5e-45ad-a176-7213c7495627">
                     <text>Figure S - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-25.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DD310E83-887F-4B4B-B431-787AF291D668">
                     <text>When dosing with more than one capsule...</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-26.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_5cd07a84-aee1-4fdf-8633-e47fdc106cc2">
                     <text>Figure T - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-27.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DC91B2D7-BD3C-4DE1-B9B0-8E0DEBA4B91B">
                     <text>Figure U - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-28.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_973e85ca-1fb6-45e4-b8a4-292ab079e5d3">
                     <text>Figure V - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-29.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="D4388922-BA52-44DF-8290-6CFAE0948335">
                     <text>Figure W - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-30.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_490fdb69-7af3-4aef-b7f1-829c5c2bc3c9">
                     <text>Figure X - IFU</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-31.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e9eba52b-4e03-4a15-92d2-7acf213e0f5f">
               <id root="21e23d90-5b63-46ac-994e-b39b7dfcd83d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 26.5 mcg Carton </title>
               <text>
                  <renderMultiMedia referencedObject="ID_5174fae4-56ae-4b98-aab6-1a839488f552" ID="id-1616448626">
                     <caption>26.5 mcg Carton</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 72964-011-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">26.5 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">For oral inhalation only<br/>
                     </content>DO NOT SWALLOW YUTREPIA CAPSULES</paragraph>
                  <paragraph>Contents:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>28 Capsules (7 Foil blister cards of 4 capsules each)</item>
                     <item>
                        <caption>•</caption>1 Dry powder inhaler</item>
                     <item>
                        <caption>•</caption>7 Single-use cleaning brushes</item>
                     <item>
                        <caption>•</caption>Instructions for Use</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
                  <paragraph>NDC 72964-011-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">26.5 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) <br/>inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Instructions for Use before each use.<br/>
                     </content>Recommended Dosage: See prescribing information.<br/>
                     <content styleCode="bold">Do not </content>remove capsules from blister cards until immediately before use.<br/>Store at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to<br/>86°F (15°C to 30°C) [see USP Controlled Room Temperature].<br/>Keep this and all drugs out of the reach of children.</paragraph>
                  <paragraph>Distributed by:<br/>Liquidia Technologies Inc.<br/>Morrisville, NC 27560</paragraph>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250523"/>
               <component>
                  <observationMedia ID="ID_5174fae4-56ae-4b98-aab6-1a839488f552">
                     <text>Principal Display Panel - 26.5 mcg Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-32.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6fcd91a5-6d5b-4af6-bc38-83343dbafe2e">
               <id root="1983d1b4-119d-4ac2-a8ce-29bbd9db0f4f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 53 mcg Carton </title>
               <text>
                  <renderMultiMedia referencedObject="AE01C782-64E4-47DF-98BD-89EFEAE7A07D" ID="id-1905437769">
                     <caption>53 mcg Carton</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 72964-012-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">53 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">For oral inhalation only<br/>
                     </content>DO NOT SWALLOW YUTREPIA CAPSULES</paragraph>
                  <paragraph>Contents:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>28 Capsules (7 Foil blister cards of 4 capsules each)</item>
                     <item>
                        <caption>•</caption>1 Dry powder inhaler</item>
                     <item>
                        <caption>•</caption>7 Single-use cleaning brushes</item>
                     <item>
                        <caption>•</caption>Instructions for Use</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
                  <paragraph>NDC 72964-012-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">26.5 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) <br/>inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Instructions for Use before each use.<br/>
                     </content>Recommended Dosage: See prescribing information.<br/>
                     <content styleCode="bold">Do not </content>remove capsules from blister cards until immediately before use.<br/>Store at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to<br/>86°F (15°C to 30°C) [see USP Controlled Room Temperature].<br/>Keep this and all drugs out of the reach of children.</paragraph>
                  <paragraph>Distributed by:<br/>Liquidia Technologies Inc.<br/>Morrisville, NC 27560</paragraph>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250523"/>
               <component>
                  <observationMedia ID="AE01C782-64E4-47DF-98BD-89EFEAE7A07D">
                     <text>Principal Display Panel - 53 mcg Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-33.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d3dc2d48-c3b8-4b8e-963e-094942a2256f">
               <id root="7a251994-8f50-4aba-9a9c-2cfc3acf1208"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 79.5 mcg Carton </title>
               <text>
                  <renderMultiMedia referencedObject="BAA84097-6DA2-4372-BA57-88F0F24AE46E" ID="id567307356">
                     <caption>79.5 mcg Carton</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 72964-013-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">79.5 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">For oral inhalation only<br/>
                     </content>DO NOT SWALLOW YUTREPIA CAPSULES</paragraph>
                  <paragraph>Contents:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>28 Capsules (7 Foil blister cards of 4 capsules each)</item>
                     <item>
                        <caption>•</caption>1 Dry powder inhaler</item>
                     <item>
                        <caption>•</caption>7 Single-use cleaning brushes</item>
                     <item>
                        <caption>•</caption>Instructions for Use</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
                  <paragraph>NDC 72964-013-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">79.5 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) <br/>inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Instructions for Use before each use.<br/>
                     </content>Recommended Dosage: See prescribing information.<br/>
                     <content styleCode="bold">Do not </content>remove capsules from blister cards until immediately before use.<br/>Store at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to<br/>86°F (15°C to 30°C) [see USP Controlled Room Temperature].<br/>Keep this and all drugs out of the reach of children.</paragraph>
                  <paragraph>Distributed by:<br/>Liquidia Technologies Inc.<br/>Morrisville, NC 27560</paragraph>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250523"/>
               <component>
                  <observationMedia ID="BAA84097-6DA2-4372-BA57-88F0F24AE46E">
                     <text>Principal Display Panel - 79.5 mcg Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-34.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3ede391b-2113-4f97-96db-e1b25b8fbca5">
               <id root="f38bc6f7-4a61-4f11-b325-2814f0ec1d45"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 106 mcg Carton </title>
               <text>
                  <renderMultiMedia referencedObject="ID_867b4014-3523-440f-a497-32c4ecf7214c" ID="id-1852094464">
                     <caption>106 mcg Carton</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 72964-014-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">106 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">For oral inhalation only<br/>
                     </content>DO NOT SWALLOW YUTREPIA CAPSULES</paragraph>
                  <paragraph>Contents:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>28 Capsules (7 Foil blister cards of 4 capsules each)</item>
                     <item>
                        <caption>•</caption>1 Dry powder inhaler</item>
                     <item>
                        <caption>•</caption>7 Single-use cleaning brushes</item>
                     <item>
                        <caption>•</caption>Instructions for Use</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
                  <paragraph>NDC 72964-014-01<br/>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">106 mcg<br/>
                     </content>per capsule</paragraph>
                  <paragraph>
                     <content styleCode="bold">Yutrepia™<br/>
                     </content>(treprostinil) <br/>inhalation powder</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read Instructions for Use before each use.<br/>
                     </content>Recommended Dosage: See prescribing information.<br/>
                     <content styleCode="bold">Do not </content>remove capsules from blister cards until immediately before use.<br/>Store at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to<br/>86°F (15°C to 30°C) [see USP Controlled Room Temperature].<br/>Keep this and all drugs out of the reach of children.</paragraph>
                  <paragraph>Distributed by:<br/>Liquidia Technologies Inc.<br/>Morrisville, NC 27560</paragraph>
                  <paragraph>
                     <content styleCode="bold">Liquidia™</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250523"/>
               <component>
                  <observationMedia ID="ID_867b4014-3523-440f-a497-32c4ecf7214c">
                     <text>Principal Display Panel - 106 mcg Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-35.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>